HALO - Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01 revenue of $102M beats by $2.31M

Halozyme Therapeutics press release (NASDAQ:HALO): Q4 Non-GAAP EPS of $0.42 beats by $0.01. Revenue of $102M (-16.2% Y/Y) beats by $2.31M. 2022 Revenue Guidance of $530 to $560 Million Representing 20-26% Growth over Reported 2021 Revenue. Recurring Revenue from Royalties in 2022 Expected to Grow by Approximately 50% over Record Royalties in 2021 to Approximately $300 Million. 2022 GAAP Diluted EPS Guidance of $1.90 to $2.05 and 2022 Non-GAAP Diluted EPS Guidance of $2.05 to $2.20.

For further details see:

Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01, revenue of $102M beats by $2.31M